Investigator-Sponsored Phase 2 Study Demonstrated Positive Results in Children with Noonan Syndrome, Idiopathic Short Stature and Other Growth-Related Conditions BioMarin-Sponsored Phase 3 Data Show Notable Mean Annualized Growth Velocity Increases in Children with Achondroplasia Who Started Treatment During Adolescence SAN RAFAEL, Calif., May 4, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that positive new data supporting the safety and efficacy of VOXZOGO® (vosoritide) in ch ...

| --- | --- | |-------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

BioMarin Pharmaceutical Inc. (BMRN) reported first-quarter 2024 adjusted earnings per share of 71 cents, beating the Zacks Consensus Estimate of 60 cents. The reported earnings rose 18.3% year over year, as higher sales were partially offset by rising R&D expenses.Total revenues were $648.8 million in the reported quarter, up 9% year over year on a reported basis and 13% on a constant currency basis. Strong sales of Voxzogo drove revenues. The top line, however, missed the Zacks Consensus Estimate of $649.8 ...

BioMarin Pharmaceutical, Inc. (NASDAQ:BMRN) Q1 2024 Earnings Conference Call April 24, 2024 4:30 PM ET Company Participants Traci McCarty - Head of IR Alexander Hardy - President & CEO Henry Fuchs - President, Worldwide Research & Development Brian Mueller - EVP & CFO Jeffrey Ajer - EVP & Chief Commercial Officer Conference Call Participants Phil Nadeau - TD Cowen Geoff Meacham - Bank of America Salveen Richter - Goldman Sachs Christopher Raymond - Piper Sandler Akash Tewari - Jefferies Jessica Fye - JPMorg ...

B!OMARIN BiOMARIN Forward-Looking Statements 4 This presentation includes both GAAP information and Non-GAAP information. Non-GAAP Income is defined by the company as GAAP Net Income excluding amortization of intangible assets, stock-based compensation expense, and, in certain periods, certain other specified items, as detailed below when applicable. The company also includes a Non-GAAP adjustment for the estimated tax impact of the reconciling items. Non-GAAP Operating Margin percentage is defined by the c ...

For the quarter ended March 2024, BioMarin Pharmaceutical (BMRN) reported revenue of $648.83 million, up 8.8% over the same period last year. EPS came in at $0.71, compared to $0.60 in the year-ago quarter.The reported revenue represents a surprise of -0.14% over the Zacks Consensus Estimate of $649.75 million. With the consensus EPS estimate being $0.60, the EPS surprise was +18.33%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to ...

BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.71 per share, beating the Zacks Consensus Estimate of $0.60 per share. This compares to earnings of $0.60 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 18.33%. A quarter ago, it was expected that this rare disease biopharmaceutical would post earnings of $0.44 per share when it actually produced earnings of $0.49, delivering a surprise of 11.36%.Over the l ...

Contact: Investors: Media: Traci McCarty Marni Kottle BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (650) 374-2803 First Quarter 2024 Total Revenues of $649 Million (+9% Y/Y and +13% at Constant Currency Y/Y); GAAP Diluted Earnings per Share (EPS) of $0.46 (+70% Y/Y) and Non-GAAP Diluted Earnings per Share of $0.71 (+18% Y/Y) VOXZOGO Net Product Revenues of $153 Million in Q1'24 (+74% Y/Y); Children Treated Increased Over 100% Y/Y For Full-year 2024 Guidance, Total Revenues Reaffi ...

Investors are always looking for stocks that are poised to beat at earnings season and BioMarin Pharmaceutical Inc. (BMRN) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because BioMarin is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pre ...

Analysts on Wall Street project that BioMarin Pharmaceutical (BMRN) will announce quarterly earnings of $0.60 per share in its forthcoming report, representing no change year over year. Revenues are projected to reach $649.75 million, increasing 8.9% from the same quarter last year.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Before a company announ ...